_MEMBER_LN_meta,_MEMBER_N0,_LogP_LN_meta,_LogP_N0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,-7.9,-4.7,hsa04510,Focal adhesion ,M11,2,0.12
1,1,-4.4,-4.3,ko04015,Rap1 signaling pathway,M11,2,0.0026
1,1,-2.9,-2.6,R-HSA-8980692,RHOA GTPase cycle,M11,2,0.03
1,1,-2.5,-3.7,R-HSA-73887,Death Receptor Signalling,M11,2,0.092
1,1,-5.6,-12,R-HSA-194315,Signaling by Rho GTPases,M11,2,0.19
1,1,-3.2,-2.5,hsa05140,Leishmania infection ,M11,2,0.06
1,1,-7.4,-3.4,ko04151,PI3K-Akt signaling pathway,M11,2,0.19
1,1,-5.4,-4.3,hsa04380,Osteoclast differentiation,M11,2,0.058
1,1,-4.8,-5.9,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M11,2,0.049
1,1,-3.4,-3.6,ko05146,Amoebiasis,M11,2,0.013
1,1,-5.1,-4.6,ko05205,Proteoglycans in cancer,M11,2,0.027
1,1,-3.1,-3.1,hsa05146,Amoebiasis,M11,2,0.0041
1,1,-3.1,-5.7,hsa05130,Pathogenic Escherichia coli infection ,M11,2,0.14
1,1,-2.3,-2.2,hsa05133,Pertussis,M11,2,0.009
1,1,-6.6,-15,R-HSA-109582,Hemostasis,M11,2,0.19
1,1,-5.2,-5,hsa04666,Fc gamma R-mediated phagocytosis ,M11,2,0.0091
1,1,-2.6,-8.4,R-HSA-9658195,Leishmania infection,M11,2,0.26
1,1,-9.5,-5.2,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M11,2,0.15
1,1,-3.9,-2.1,hsa05152,Tuberculosis,M11,2,0.14
1,1,-5.5,-2.8,R-HSA-425407,SLC-mediated transmembrane transport,M11,2,0.16
1,1,-5.4,-11,hsa04514,Cell adhesion molecules (CAMs) ,M11,2,0.18
1,1,-2.2,-2.2,R-HSA-157118,Signaling by NOTCH,M11,2,0.0072
1,1,-9.8,-2.7,ko04530,Tight junction,M11,2,0.28
1,1,-4.2,-4.2,hsa04015,Rap1 signaling pathway,M11,2,0.003
1,1,-2.4,-7.3,hsa05142,Chagas disease (American trypanosomiasis),M11,2,0.25
1,1,-2,-2.4,hsa04024,cAMP signaling pathway,M11,2,0.037
1,1,-8.6,-8.6,R-HSA-6798695,Neutrophil degranulation,M11,2,0.002
1,1,-2.4,-5.5,ko04670,Leukocyte transendothelial migration,M11,2,0.2
1,1,-3.1,-5.7,ko05130,Pathogenic Escherichia coli infection,M11,2,0.14
1,1,-6.2,-4.1,hsa05205,Proteoglycans in cancer,M11,2,0.1
1,1,-4.2,-2.1,ko05152,Tuberculosis,M11,2,0.16
1,1,-2.3,-8.7,R-HSA-9664407,Parasite infection,M11,2,0.29
1,1,-5,-7.3,R-HSA-5653656,Vesicle-mediated transport,M11,2,0.093
1,1,-3.6,-4.4,R-HSA-199418,Negative regulation of the PI3K/AKT network,M11,2,0.05
1,1,-4.4,-2.6,hsa04390,Hippo signaling pathway,M11,2,0.13
1,1,-5.6,-2.8,hsa04145,Phagosome,M11,2,0.17
1,1,-5.4,-11,ko04514,Cell adhesion molecules (CAMs),M11,2,0.18
1,1,-5.6,-3.2,R-HSA-1500931,Cell-Cell communication,M11,2,0.14
1,1,-2.2,-6.6,hsa04640,Hematopoietic cell lineage ,M11,2,0.25
1,1,-2.2,-4.9,hsa05144,Malaria,M11,2,0.19
1,1,-2.3,-7.8,hsa05166,HTLV-I infection,M11,2,0.27
1,1,-2,-2.4,R-HSA-182971,EGFR downregulation,M11,2,0.044
1,1,-9.8,-2.7,hsa04530,Tight junction ,M11,2,0.28
1,1,-7.9,-4.7,ko04510,Focal adhesion,M11,2,0.12
1,1,-2.2,-2.1,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M11,2,0.017
1,1,-3.2,-2.5,ko05140,Leishmaniasis,M11,2,0.06
1,1,-2.7,-3.9,R-HSA-9013148,CDC42 GTPase cycle,M11,2,0.091
1,1,-3.8,-2.6,hsa04520,Adherens junction ,M11,2,0.095
1,1,-5.8,-13,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M11,2,0.19
1,1,-2.3,-8.7,R-HSA-9664417,Leishmania phagocytosis,M11,2,0.29
1,1,-2.4,-3.7,R-HSA-112315,Transmission across Chemical Synapses,M11,2,0.11
1,1,-5.2,-3.5,R-HSA-76005,Response to elevated platelet cytosolic Ca2+,M11,2,0.1
1,1,-3.6,-3.2,ko04390,Hippo signaling pathway,M11,2,0.031
1,1,-2.3,-7.8,ko05166,HTLV-I infection,M11,2,0.27
1,1,-5.6,-3.2,R-HSA-114608,Platelet degranulation ,M11,2,0.14
1,1,-11,-3.3,R-HSA-382551,Transport of small molecules,M11,2,0.27
1,1,-3.2,-4.2,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M11,2,0.067
1,1,-3.2,-3.1,R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,M11,2,0.0054
1,1,-2.8,-8.7,hsa05416,Viral myocarditis ,M11,2,0.25
1,1,-3.6,-7.7,ko04810,Regulation of actin cytoskeleton,M11,2,0.18
1,1,-3.3,-2.3,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M11,2,0.093
1,1,-5.2,-2.4,R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,M11,2,0.19
1,1,-7.9,-3.2,hsa04151,PI3K-Akt signaling pathway,M11,2,0.21
1,1,-5.5,-4.1,ko04380,Osteoclast differentiation,M11,2,0.073
1,1,-24,-5.8,R-HSA-422475,Axon guidance,M11,2,0.3
1,1,-2.3,-6.9,ko05142,Chagas disease (American trypanosomiasis),M11,2,0.25
1,1,-5.2,-5,ko04666,Fc gamma R-mediated phagocytosis,M11,2,0.0091
1,1,-2.8,-6.8,ko05132,Salmonella infection,M11,2,0.21
1,1,-4.8,-4.4,hsa04014,Ras signaling pathway,M11,2,0.02
1,1,-3.5,-6.1,hsa05132,Salmonella infection,M11,2,0.14
1,1,-2.4,-5.5,hsa04670,Leukocyte transendothelial migration ,M11,2,0.2
1,1,-2.8,-3.4,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,M11,2,0.042
1,1,-5.6,-2.8,ko04145,Phagosome,M11,2,0.17
1,1,-2.1,-3.4,hsa05323,Rheumatoid arthritis,M11,2,0.12
1,1,-2.5,-3.3,ko05323,Rheumatoid arthritis,M11,2,0.067
1,1,-3.8,-2.6,ko04520,Adherens junction,M11,2,0.095
1,1,-3.3,-2.9,R-HSA-112316,Neuronal System,M11,2,0.032
1,1,-2.4,-2.3,R-HSA-352230,Amino acid transport across the plasma membrane,M11,2,0.013
1,1,-2.6,-19,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M11,2,0.38
1,1,-3.3,-5.5,R-HSA-8856828,Clathrin-mediated endocytosis,M11,2,0.12
1,1,-25,-6.2,R-HSA-9675108,Nervous system development,M11,2,0.3
1,1,-2.1,-2.5,R-HSA-177929,Signaling by EGFR,M11,2,0.051
1,1,-15,-2.6,R-HSA-376176,Signaling by ROBO receptors,M11,2,0.36
1,1,-2.8,-6.8,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M11,2,0.21
1,1,-2.6,-2.4,ko05133,Pertussis,M11,2,0.017
1,1,-2,-3.1,R-HSA-194138,Signaling by VEGF,M11,2,0.1
1,1,-2.3,-8.7,R-HSA-9664422,FCGR3A-mediated phagocytosis,M11,2,0.29
1,1,-2.4,-4.6,ko04010,MAPK signaling pathway,M11,2,0.16
1,1,-10,-5.5,hsa05200,Pathways in cancer ,M11,2,0.15
1,1,-3.6,-7.7,hsa04810,Regulation of actin cytoskeleton ,M11,2,0.18
1,1,-2.9,-6.3,R-HSA-9013149,RAC1 GTPase cycle,M11,2,0.19
1,1,-2.2,-6.6,ko04640,Hematopoietic cell lineage,M11,2,0.25
1,1,-3,-4.1,hsa05202,Transcriptional misregulation in cancer,M11,2,0.075
1,1,-7,-6.5,R-HSA-9012999,RHO GTPase cycle,M11,2,0.021
1,1,-3.8,-4.1,ko05202,Transcriptional misregulation in cancer,M11,2,0.02
1,1,-2.4,-4.6,hsa04010,MAPK signaling pathway ,M11,2,0.16
1,1,-3.4,-9.6,R-HSA-76002,"Platelet activation, signaling and aggregation",M11,2,0.24
0,1,0,-6.4,R-HSA-1236974,ER-Phagosome pathway,M01,1,0.37
0,1,0,-2.1,R-HSA-448706,Interleukin-1 processing,M01,1,0.18
1,0,-2.1,0,R-HSA-8935964,RUNX1 regulates expression of components of tight junctions,M10,1,0.18
0,1,0,-2.7,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M01,1,0.23
0,1,0,-2.7,hsa04664,Fc epsilon RI signaling pathway ,M01,1,0.23
0,1,0,-8.5,hsa05320,Autoimmune thyroid disease ,M01,1,0.39
0,1,0,-2.7,ko04115,p53 signaling pathway,M01,1,0.23
1,0,-2,0,hsa04668,TNF signaling pathway,M10,1,0.17
1,0,-12,0,ko00980,Metabolism of xenobiotics by cytochrome P450,M10,1,0.42
0,1,0,-3.1,R-HSA-9664433,Leishmania parasite growth and survival,M01,1,0.26
0,1,0,-2.7,R-HSA-9634600,"Regulation of glycolysis by fructose 2,6-bisphosphate metabolism",M01,1,0.23
0,1,0,-8.3,R-HSA-202430,Translocation of ZAP-70 to Immunological synapse,M01,1,0.39
1,0,-2.2,0,ko04330,Notch signaling pathway,M10,1,0.19
1,0,-3.6,0,hsa05231,Choline metabolism in cancer,M10,1,0.28
0,1,0,-3.2,R-HSA-8985947,Interleukin-9 signaling,M01,1,0.26
1,0,-10,0,R-HSA-2262752,Cellular responses to stress,M10,1,0.41
0,1,0,-4.3,R-HSA-164938,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,M01,1,0.31
0,1,0,-3.8,R-HSA-389359,CD28 dependent Vav1 pathway,M01,1,0.29
0,1,0,-8.5,ko05320,Autoimmune thyroid disease,M01,1,0.39
1,0,-2.2,0,hsa04920,Adipocytokine signaling pathway ,M10,1,0.18
1,0,-4.4,0,hsa05322,Systemic lupus erythematosus ,M10,1,0.32
0,1,0,-3.2,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M01,1,0.26
0,1,0,-2.9,R-HSA-373755,Semaphorin interactions,M01,1,0.24
1,0,-4.4,0,ko05322,Systemic lupus erythematosus,M10,1,0.32
1,0,-2.2,0,ko04213,Longevity regulating pathway - multiple species,M10,1,0.18
0,1,0,-2.1,R-HSA-901042,Calnexin/calreticulin cycle,M01,1,0.18
1,0,-2.3,0,hsa04371,Apelin signaling pathway,M10,1,0.2
1,0,-2.1,0,ko00030,Pentose phosphate pathway,M10,1,0.18
1,0,-16,0,R-HSA-168255,Influenza Infection,M10,1,0.44
1,0,-2.1,0,hsa04961,Endocrine and other factor-regulated calcium reabsorption,M10,1,0.17
0,1,0,-3.9,hsa05168,Herpes simplex infection,M01,1,0.3
0,1,0,-4.1,R-HSA-109581,Apoptosis,M01,1,0.3
1,0,-2.2,0,ko04920,Adipocytokine signaling pathway,M10,1,0.18
1,0,-3.4,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M10,1,0.27
1,0,-3.3,0,R-HSA-3000171,Non-integrin membrane-ECM interactions,M10,1,0.27
0,1,0,-2.9,R-HSA-453276,Regulation of mitotic cell cycle,M01,1,0.24
1,0,-3.4,0,R-HSA-388844,Receptor-type tyrosine-protein phosphatases,M10,1,0.27
1,0,-3.3,0,ko04072,Phospholipase D signaling pathway,M10,1,0.27
0,1,0,-8.8,R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,M01,1,0.4
0,1,0,-6.7,R-HSA-1236977,Endosomal/Vacuolar pathway,M01,1,0.37
0,1,0,-3.8,R-HSA-9006925,Intracellular signaling by second messengers,M01,1,0.29
0,1,0,-4.2,R-HSA-168638,NOD1/2 Signaling Pathway,M01,1,0.31
1,0,-2.6,0,R-HSA-1989781,PPARA activates gene expression,M10,1,0.22
1,0,-2.8,0,ko00340,Histidine metabolism,M10,1,0.24
1,0,-4.6,0,R-HSA-3906995,Diseases associated with O-glycosylation of proteins,M10,1,0.32
0,1,0,-3,ko05164,Influenza A,M01,1,0.25
1,0,-15,0,R-HSA-211859,Biological oxidations,M10,1,0.44
1,0,-2.2,0,hsa04020,Calcium signaling pathway ,M10,1,0.18
0,1,0,-17,hsa04660,T cell receptor signaling pathway ,M01,1,0.44
0,1,0,-2.1,R-HSA-70221,Glycogen breakdown (glycogenolysis),M01,1,0.17
0,1,0,-2.1,R-HSA-179409,APC-Cdc20 mediated degradation of Nek2A,M01,1,0.18
0,1,0,-2.3,R-HSA-375276,Peptide ligand-binding receptors,M01,1,0.19
1,0,-2.3,0,R-HSA-77111,Synthesis of Ketone Bodies,M10,1,0.2
1,0,-3.1,0,hsa04974,Protein digestion and absorption,M10,1,0.26
0,1,0,-9.3,R-HSA-2424491,DAP12 signaling,M01,1,0.4
0,1,0,-3.1,R-HSA-163685,Integration of energy metabolism,M01,1,0.25
1,0,-3.6,0,ko04360,Axon guidance,M10,1,0.28
0,1,0,-2.4,R-HSA-392170,ADP signalling through P2Y purinoceptor 12,M01,1,0.21
0,1,0,-9,ko05340,Primary immunodeficiency,M01,1,0.4
1,0,-2.6,0,R-HSA-5578775,Ion homeostasis,M10,1,0.22
1,0,-2.8,0,R-HSA-74182,Ketone body metabolism,M10,1,0.24
1,0,-3,0,R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",M10,1,0.25
1,0,-2.5,0,ko04917,Prolactin signaling pathway,M10,1,0.21
1,0,-2.8,0,ko04012,ErbB signaling pathway,M10,1,0.23
0,1,0,-7.7,R-HSA-418594,G alpha (i) signalling events,M01,1,0.38
0,1,0,-2.6,R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),M01,1,0.22
0,1,0,-2.4,R-HSA-451326,Activation of kainate receptors upon glutamate binding,M01,1,0.2
1,0,-25,0,R-HSA-192823,Viral mRNA Translation,M10,1,0.46
0,1,0,-3,R-HSA-449836,Other interleukin signaling,M01,1,0.25
0,1,0,-4.9,R-HSA-983169,Class I MHC mediated antigen processing & presentation,M01,1,0.33
0,1,0,-2.2,M00075,"N-glycan biosynthesis, complex type",M01,1,0.18
0,1,0,-3.9,R-HSA-9679506,SARS-CoV Infections,M01,1,0.3
0,1,0,-4.5,R-HSA-3928662,EPHB-mediated forward signaling,M01,1,0.32
1,0,-3.5,0,R-HSA-156584,Cytosolic sulfonation of small molecules,M10,1,0.28
0,1,0,-12,hsa05169,Epstein-Barr virus infection,M01,1,0.42
0,1,0,-14,ko04659,Th17 cell differentiation,M01,1,0.43
0,1,0,-6.7,ko04630,Jak-STAT signaling pathway,M01,1,0.37
0,1,0,-5,R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,M01,1,0.33
1,0,-2.1,0,R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,M10,1,0.17
1,0,-2.3,0,R-HSA-163765,ChREBP activates metabolic gene expression,M10,1,0.2
0,1,0,-2.6,R-HSA-6802957,Oncogenic MAPK signaling,M01,1,0.22
0,1,0,-3.2,hsa05032,Morphine addiction,M01,1,0.26
0,1,0,-3,R-HSA-389356,CD28 co-stimulation,M01,1,0.25
1,0,-8.6,0,ko00480,Glutathione metabolism,M10,1,0.4
0,1,0,-2.1,R-HSA-9660826,Purinergic signaling in leishmaniasis infection,M01,1,0.18
0,1,0,-2.2,R-HSA-418592,ADP signalling through P2Y purinoceptor 1,M01,1,0.18
1,0,-2.4,0,R-HSA-180292,GAB1 signalosome,M10,1,0.2
1,0,-2.3,0,R-HSA-5638302,Signaling by Overexpressed Wild-Type EGFR in Cancer,M10,1,0.2
1,0,-17,0,R-HSA-168273,Influenza Viral RNA Transcription and Replication,M10,1,0.44
0,1,0,-2.6,hsa04672,Intestinal immune network for IgA production ,M01,1,0.22
0,1,0,-11,ko05330,Allograft rejection,M01,1,0.42
1,0,-2.9,0,R-HSA-1638074,Keratan sulfate/keratin metabolism,M10,1,0.24
1,0,-3.6,0,R-HSA-6794362,Protein-protein interactions at synapses,M10,1,0.28
1,0,-3,0,hsa04915,Estrogen signaling pathway,M10,1,0.25
0,1,0,-2.6,R-HSA-168927,"TICAM1, RIP1-mediated IKK complex recruitment",M01,1,0.22
1,0,-2.2,0,hsa05217,Basal cell carcinoma ,M10,1,0.18
1,0,-4.3,0,R-HSA-4420332,Defective B3GALT6 causes EDSP2 and SEMDJL1,M10,1,0.31
1,0,-4.4,0,R-HSA-2142753,Arachidonic acid metabolism,M10,1,0.32
0,1,0,-4.6,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M01,1,0.32
0,1,0,-3.9,ko04114,Oocyte meiosis,M01,1,0.3
1,0,-2.1,0,R-HSA-426048,Arachidonate production from DAG,M10,1,0.18
0,1,0,-12,ko04612,Antigen processing and presentation,M01,1,0.42
0,1,0,-2.8,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M01,1,0.23
0,1,0,-2,R-HSA-9635486,Infection with Mycobacterium tuberculosis,M01,1,0.17
0,1,0,-2.3,R-HSA-445989,TAK1 activates NFkB by phosphorylation and activation of IKKs complex,M01,1,0.2
1,0,-24,0,R-HSA-975956,Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),M10,1,0.46
0,1,0,-2.8,ko04921,Oxytocin signaling pathway,M01,1,0.24
1,0,-6.3,0,R-HSA-446728,Cell junction organization,M10,1,0.36
1,0,-2.2,0,hsa00591,Linoleic acid metabolism ,M10,1,0.19
1,0,-3,0,R-HSA-2243919,Crosslinking of collagen fibrils,M10,1,0.25
0,1,0,-3.6,R-HSA-5357905,Regulation of TNFR1 signaling,M01,1,0.28
1,0,-2,0,hsa04142,Lysosome ,M10,1,0.17
1,0,-2.6,0,hsa00564,Glycerophospholipid metabolism ,M10,1,0.23
0,1,0,-6.7,R-HSA-180024,DARPP-32 events,M01,1,0.37
1,0,-5.3,0,ko04152,AMPK signaling pathway,M10,1,0.34
0,1,0,-12,ko05332,Graft-versus-host disease,M01,1,0.42
1,0,-3,0,R-HSA-425397,"Transport of vitamins, nucleosides, and related molecules",M10,1,0.25
0,1,0,-3.4,R-HSA-164944,Nef and signal transduction,M01,1,0.28
0,1,0,-2.6,hsa04722,Neurotrophin signaling pathway ,M01,1,0.23
1,0,-2.1,0,R-HSA-5666185,RHO GTPases Activate Rhotekin and Rhophilins,M10,1,0.18
0,1,0,-3.9,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M01,1,0.3
1,0,-2,0,ko04668,TNF signaling pathway,M10,1,0.17
0,1,0,-2.6,ko04672,Intestinal immune network for IgA production,M01,1,0.22
0,1,0,-2.1,R-HSA-1169408,ISG15 antiviral mechanism,M01,1,0.17
1,0,-4.6,0,ko05224,Breast cancer,M10,1,0.32
0,1,0,-2.8,R-HSA-1296065,Inwardly rectifying K+ channels,M01,1,0.24
1,0,-2.3,0,R-HSA-977606,Regulation of Complement cascade,M10,1,0.19
0,1,0,-4.5,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M01,1,0.32
1,0,-2.1,0,ko05030,Cocaine addiction,M10,1,0.18
0,1,0,-21,R-HSA-449147,Signaling by Interleukins,M01,1,0.45
0,1,0,-8.8,R-HSA-5683057,MAPK family signaling cascades,M01,1,0.4
1,0,-2.1,0,hsa04912,GnRH signaling pathway ,M10,1,0.17
0,1,0,-7.2,hsa05162,Measles,M01,1,0.38
1,0,-6.5,0,R-HSA-211945,Phase I - Functionalization of compounds,M10,1,0.37
1,0,-2,0,R-HSA-2132295,MHC class II antigen presentation,M10,1,0.17
1,0,-2,0,ko04142,Lysosome,M10,1,0.17
0,1,0,-2.7,R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,M01,1,0.23
0,1,0,-4.2,R-HSA-446652,Interleukin-1 family signaling,M01,1,0.31
1,0,-4.7,0,hsa04152,AMPK signaling pathway,M10,1,0.32
1,0,-2.3,0,R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,M10,1,0.2
1,0,-2.9,0,R-HSA-1236394,Signaling by ERBB4,M10,1,0.24
0,1,0,-5.6,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M01,1,0.35
1,0,-6,0,R-HSA-1650814,Collagen biosynthesis and modifying enzymes,M10,1,0.36
0,1,0,-2.6,R-HSA-5625900,RHO GTPases activate CIT,M01,1,0.22
1,0,-3.1,0,ko00601,Glycosphingolipid biosynthesis - lacto and neolacto series,M10,1,0.26
1,0,-10,0,ko05418,Fluid shear stress and atherosclerosis,M10,1,0.41
0,1,0,-3.3,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M01,1,0.27
1,0,-2.2,0,R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,M10,1,0.19
0,1,0,-3.1,R-HSA-1257604,PIP3 activates AKT signaling,M01,1,0.26
0,1,0,-3.4,R-HSA-1640170,Cell Cycle,M01,1,0.27
0,1,0,-4.4,hsa04621,NOD-like receptor signaling pathway ,M01,1,0.32
1,0,-2,0,hsa00410,beta-Alanine metabolism ,M10,1,0.17
1,0,-2.3,0,hsa05215,Prostate cancer ,M10,1,0.2
0,1,0,-3.7,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M01,1,0.29
0,1,0,-3.5,ko05100,Bacterial invasion of epithelial cells,M01,1,0.28
0,1,0,-3.5,hsa04728,Dopaminergic synapse,M01,1,0.28
0,1,0,-4.4,ko05143,African trypanosomiasis,M01,1,0.32
1,0,-3.6,0,hsa04360,Axon guidance ,M10,1,0.28
0,1,0,-2.7,R-HSA-9649948,Signaling downstream of RAS mutants,M01,1,0.23
0,1,0,-3.2,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M01,1,0.26
0,1,0,-2.1,R-HSA-69236,G1 Phase,M01,1,0.18
0,1,0,-3,R-HSA-392518,Signal amplification,M01,1,0.25
0,1,0,-3.7,R-HSA-909733,Interferon alpha/beta signaling,M01,1,0.29
1,0,-13,0,hsa03010,Ribosome ,M10,1,0.43
1,0,-2.2,0,R-HSA-8847993,ERBB2 Activates PTK6 Signaling,M10,1,0.19
1,0,-22,0,R-HSA-2408522,Selenoamino acid metabolism,M10,1,0.46
0,1,0,-2.2,R-HSA-937041,IKK complex recruitment mediated by RIP1,M01,1,0.18
1,0,-3,0,hsa02010,ABC transporters ,M10,1,0.25
0,1,0,-7.6,ko04144,Endocytosis,M01,1,0.38
0,1,0,-15,hsa04659,Th17 cell differentiation,M01,1,0.44
1,0,-9.3,0,R-HSA-8957275,Post-translational protein phosphorylation,M10,1,0.4
1,0,-7.9,0,ko05410,Hypertrophic cardiomyopathy (HCM),M10,1,0.39
0,1,0,-17,hsa04650,Natural killer cell mediated cytotoxicity ,M01,1,0.44
0,1,0,-2.7,ko04024,cAMP signaling pathway,M01,1,0.23
0,1,0,-5.2,hsa05203,Viral carcinogenesis,M01,1,0.34
1,0,-2.7,0,R-HSA-1482839,Acyl chain remodelling of PE,M10,1,0.23
1,0,-2.3,0,R-HSA-5638303,Inhibition of Signaling by Overexpressed EGFR,M10,1,0.2
0,1,0,-6.3,R-HSA-9020558,Interleukin-2 signaling,M01,1,0.36
1,0,-2.8,0,hsa04012,ErbB signaling pathway ,M10,1,0.23
1,0,-6,0,hsa04310,Wnt signaling pathway ,M10,1,0.36
1,0,-2.2,0,R-HSA-5140745,"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",M10,1,0.19
0,1,0,-10,R-HSA-388841,Costimulation by the CD28 family,M01,1,0.41
0,1,0,-9.5,hsa05321,Inflammatory bowel disease (IBD),M01,1,0.4
0,1,0,-3.6,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M01,1,0.28
0,1,0,-3.4,R-HSA-5669034,TNFs bind their physiological receptors,M01,1,0.27
0,1,0,-6.3,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M01,1,0.36
0,1,0,-3.9,ko05168,Herpes simplex infection,M01,1,0.3
0,1,0,-2.2,R-HSA-202040,G-protein activation,M01,1,0.19
1,0,-17,0,R-HSA-1474244,Extracellular matrix organization,M10,1,0.44
1,0,-2.9,0,R-HSA-3656237,Defective EXT2 causes exostoses 2,M10,1,0.24
0,1,0,-3,R-HSA-381676,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,M01,1,0.25
1,0,-4.2,0,ko01524,Platinum drug resistance,M10,1,0.31
0,1,0,-2.3,R-HSA-6802952,Signaling by BRAF and RAF fusions,M01,1,0.19
1,0,-5.4,0,R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,M10,1,0.34
1,0,-4,0,R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,M10,1,0.3
1,0,-2.1,0,R-HSA-8957322,Metabolism of steroids,M10,1,0.18
1,0,-4.3,0,R-HSA-2029481,FCGR activation,M10,1,0.31
1,0,-2.8,0,R-HSA-977068,Termination of O-glycan biosynthesis,M10,1,0.24
1,0,-11,0,ko00982,Drug metabolism - cytochrome P450,M10,1,0.42
0,1,0,-3.4,R-HSA-8983432,Interleukin-15 signaling,M01,1,0.27
1,0,-2.4,0,R-HSA-2024096,HS-GAG degradation,M10,1,0.2
0,1,0,-2.2,R-HSA-72172,mRNA Splicing,M01,1,0.18
0,1,0,-2.7,R-HSA-9679191,Potential therapeutics for SARS,M01,1,0.23
1,0,-15,0,R-HSA-71291,Metabolism of amino acids and derivatives,M10,1,0.44
1,0,-5.6,0,R-HSA-5173105,O-linked glycosylation,M10,1,0.35
0,1,0,-4,R-HSA-5218859,Regulated Necrosis,M01,1,0.3
1,0,-2.5,0,R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",M10,1,0.21
0,1,0,-7.8,R-HSA-202733,Cell surface interactions at the vascular wall,M01,1,0.39
0,1,0,-7.6,hsa04144,Endocytosis ,M01,1,0.38
1,0,-2.6,0,R-HSA-1227990,Signaling by ERBB2 in Cancer,M10,1,0.22
0,1,0,-2.4,ko04971,Gastric acid secretion,M01,1,0.21
0,1,0,-3.3,ko05032,Morphine addiction,M01,1,0.27
1,0,-2.1,0,R-HSA-9032759,NTRK2 activates RAC1,M10,1,0.18
1,0,-25,0,R-HSA-156842,Eukaryotic Translation Elongation,M10,1,0.46
1,0,-2.8,0,hsa04072,Phospholipase D signaling pathway,M10,1,0.24
0,1,0,-6.6,ko05169,Epstein-Barr virus infection,M01,1,0.37
0,1,0,-5.4,R-HSA-912526,Interleukin receptor SHC signaling,M01,1,0.34
1,0,-6,0,ko05150,Staphylococcus aureus infection,M10,1,0.36
1,0,-2.1,0,hsa04350,TGF-beta signaling pathway ,M10,1,0.18
0,1,0,-2.6,R-HSA-9607240,FLT3 Signaling,M01,1,0.22
1,0,-13,0,R-HSA-72695,"Formation of the ternary complex, and subsequently, the 43S complex",M10,1,0.43
1,0,-11,0,R-HSA-3000178,ECM proteoglycans,M10,1,0.42
1,0,-2.8,0,R-HSA-9013406,RHOQ GTPase cycle,M10,1,0.24
0,1,0,-2.8,R-HSA-8953854,Metabolism of RNA,M01,1,0.23
1,0,-4.1,0,ko05231,Choline metabolism in cancer,M10,1,0.3
1,0,-23,0,R-HSA-2408557,Selenocysteine synthesis,M10,1,0.46
1,0,-4,0,R-HSA-1251932,PLCG1 events in ERBB2 signaling,M10,1,0.3
1,0,-12,0,R-HSA-390522,Striated Muscle Contraction,M10,1,0.42
0,1,0,-2.1,R-HSA-69231,Cyclin D associated events in G1,M01,1,0.18
1,0,-2.5,0,R-HSA-193704,p75 NTR receptor-mediated signalling,M10,1,0.22
0,1,0,-2.7,hsa05131,Shigellosis,M01,1,0.23
0,1,0,-3.4,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling ,M01,1,0.27
0,1,0,-4,R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",M01,1,0.3
1,0,-2.7,0,R-HSA-189483,Heme degradation,M10,1,0.23
0,1,0,-2.6,ko04722,Neurotrophin signaling pathway,M01,1,0.23
1,0,-4,0,R-HSA-9663891,Selective autophagy,M10,1,0.3
1,0,-2.4,0,R-HSA-8964043,Plasma lipoprotein clearance,M10,1,0.21
1,0,-4.3,0,R-HSA-8948216,Collagen chain trimerization,M10,1,0.31
0,1,0,-2.9,R-HSA-8854691,Interleukin-20 family signaling,M01,1,0.25
0,1,0,-12,R-HSA-202433,Generation of second messenger molecules,M01,1,0.42
1,0,-2.1,0,R-HSA-1483249,Inositol phosphate metabolism,M10,1,0.17
0,1,0,-2.7,R-HSA-6802949,Signaling by RAS mutants,M01,1,0.23
1,0,-2.2,0,hsa05120,Epithelial cell signaling in Helicobacter pylori infection ,M10,1,0.19
1,0,-2.2,0,ko05034,Alcoholism,M10,1,0.19
1,0,-6,0,ko03320,PPAR signaling pathway,M10,1,0.36
0,1,0,-2.7,hsa05145,Toxoplasmosis,M01,1,0.23
1,0,-5.5,0,R-HSA-1630316,Glycosaminoglycan metabolism,M10,1,0.35
0,1,0,-5.5,ko05144,Malaria,M01,1,0.35
0,1,0,-2.2,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M01,1,0.19
0,1,0,-5,R-HSA-416476,G alpha (q) signalling events,M01,1,0.33
1,0,-2.6,0,ko05218,Melanoma,M10,1,0.22
1,0,-2.6,0,R-HSA-71288,Creatine metabolism,M10,1,0.22
1,0,-12,0,R-HSA-72649,Translation initiation complex formation,M10,1,0.42
0,1,0,-2.8,ko04720,Long-term potentiation,M01,1,0.24
0,1,0,-5.6,R-HSA-9020958,Interleukin-21 signaling,M01,1,0.35
1,0,-7.9,0,hsa05410,Hypertrophic cardiomyopathy (HCM) ,M10,1,0.39
0,1,0,-2.7,R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,M01,1,0.23
1,0,-2.2,0,ko00760,Nicotinate and nicotinamide metabolism,M10,1,0.19
1,0,-3.3,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M10,1,0.27
0,1,0,-3.4,R-HSA-9005895,Pervasive developmental disorders,M01,1,0.27
0,1,0,-10,hsa04062,Chemokine signaling pathway ,M01,1,0.41
0,1,0,-3.6,hsa05143,African trypanosomiasis,M01,1,0.28
1,0,-24,0,R-HSA-72737,Cap-dependent Translation Initiation,M10,1,0.46
1,0,-12,0,ko05204,Chemical carcinogenesis,M10,1,0.42
1,0,-10,0,R-HSA-72766,Translation,M10,1,0.41
0,1,0,-17,hsa04060,Cytokine-cytokine receptor interaction ,M01,1,0.44
0,1,0,-3.4,R-HSA-9675151,Disorders of Developmental Biology,M01,1,0.27
0,1,0,-12,hsa05332,Graft-versus-host disease ,M01,1,0.42
1,0,-2.4,0,hsa_M00006,"Pentose phosphate pathway, oxidative phase, glucose 6P => ribulose 5P",M10,1,0.21
0,1,0,-2.6,R-HSA-418597,G alpha (z) signalling events,M01,1,0.23
1,0,-2.6,0,R-HSA-2028269,Signaling by Hippo,M10,1,0.23
1,0,-3.6,0,R-HSA-3000480,Scavenging by Class A Receptors,M10,1,0.28
0,1,0,-2.9,R-HSA-109606,Intrinsic Pathway for Apoptosis,M01,1,0.24
1,0,-2.7,0,ko00592,alpha-Linolenic acid metabolism,M10,1,0.23
1,0,-2.8,0,hsa00561,Glycerolipid metabolism ,M10,1,0.24
0,1,0,-3.5,R-HSA-5627117,RHO GTPases Activate ROCKs,M01,1,0.28
0,1,0,-3.1,R-HSA-9013423,RAC3 GTPase cycle,M01,1,0.26
1,0,-2.3,0,R-HSA-8850843,Phosphate bond hydrolysis by NTPDase proteins,M10,1,0.2
1,0,-2,0,R-HSA-1643713,Signaling by EGFR in Cancer,M10,1,0.17
1,0,-12,0,R-HSA-72702,Ribosomal scanning and start codon recognition,M10,1,0.42
0,1,0,-3.1,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M01,1,0.26
1,0,-2.1,0,R-HSA-525793,Myogenesis,M10,1,0.18
0,1,0,-2.6,R-HSA-8876384,Listeria monocytogenes entry into host cells,M01,1,0.22
0,1,0,-2.9,R-HSA-400685,Sema4D in semaphorin signaling,M01,1,0.25
0,1,0,-2.6,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M01,1,0.22
0,1,0,-8.7,R-HSA-195258,RHO GTPase Effectors,M01,1,0.4
1,0,-2.1,0,R-HSA-9646399,Aggrephagy,M10,1,0.18
1,0,-3,0,ko02010,ABC transporters,M10,1,0.25
0,1,0,-3,R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,M01,1,0.25
0,1,0,-3.5,R-HSA-168898,Toll-like Receptor Cascades,M01,1,0.28
0,1,0,-2.2,hsa_M00075,"N-glycan biosynthesis, complex type",M01,1,0.18
0,1,0,-2.1,R-HSA-9020933,Interleukin-23 signaling,M01,1,0.18
0,1,0,-6.1,R-HSA-389948,PD-1 signaling,M01,1,0.36
1,0,-3,0,R-HSA-2022854,Keratan sulfate biosynthesis,M10,1,0.25
1,0,-2.7,0,R-HSA-6807878,COPI-mediated anterograde transport,M10,1,0.23
1,0,-2.1,0,ko04350,TGF-beta signaling pathway,M10,1,0.18
0,1,0,-2.4,R-HSA-5663220,RHO GTPases Activate Formins,M01,1,0.21
1,0,-3.4,0,hsanan03,glycosphingolipid biosynthesis,M10,1,0.27
1,0,-2.3,0,R-HSA-192105,Synthesis of bile acids and bile salts,M10,1,0.2
1,0,-4,0,R-HSA-375165,NCAM signaling for neurite out-growth,M10,1,0.3
0,1,0,-30,R-HSA-1280218,Adaptive Immune System,M01,1,0.47
0,1,0,-8.4,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M01,1,0.39
1,0,-2.2,0,R-HSA-5205647,Mitophagy,M10,1,0.19
0,1,0,-3.8,R-HSA-416482,G alpha (12/13) signalling events,M01,1,0.29
0,1,0,-2.7,ko04664,Fc epsilon RI signaling pathway,M01,1,0.23
1,0,-2.8,0,hsa00350,Tyrosine metabolism ,M10,1,0.24
1,0,-2.4,0,R-HSA-1632852,Macroautophagy,M10,1,0.21
0,1,0,-3.6,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M01,1,0.28
0,1,0,-6.4,R-HSA-877300,Interferon gamma signaling,M01,1,0.36
1,0,-4.2,0,hsa01524,Platinum drug resistance,M10,1,0.31
1,0,-5.5,0,R-HSA-196854,Metabolism of vitamins and cofactors,M10,1,0.35
0,1,0,-9,hsa05340,Primary immunodeficiency ,M01,1,0.4
1,0,-4.2,0,hsa00010,Glycolysis / Gluconeogenesis ,M10,1,0.31
1,0,-5.9,0,R-HSA-1474290,Collagen formation,M10,1,0.35
1,0,-3.2,0,ko01521,EGFR tyrosine kinase inhibitor resistance,M10,1,0.26
0,1,0,-5.6,R-HSA-2682334,EPH-Ephrin signaling,M01,1,0.35
0,1,0,-11,hsa05330,Allograft rejection ,M01,1,0.42
1,0,-16,0,R-HSA-9711097,Cellular response to starvation,M10,1,0.44
0,1,0,-4.3,R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,M01,1,0.31
0,1,0,-2.5,R-HSA-5357786,TNFR1-induced proapoptotic signaling,M01,1,0.22
1,0,-26,0,R-HSA-156902,Peptide chain elongation,M10,1,0.46
1,0,-2,0,ko01523,Antifolate resistance,M10,1,0.17
1,0,-2.3,0,R-HSA-445355,Smooth Muscle Contraction,M10,1,0.2
1,0,-3.1,0,hsa00601,Glycosphingolipid biosynthesis - lacto and neolacto series ,M10,1,0.26
0,1,0,-6.7,R-HSA-913531,Interferon Signaling,M01,1,0.37
1,0,-2.1,0,R-HSA-8874081,MET activates PTK2 signaling,M10,1,0.18
1,0,-8,0,hsa04512,ECM-receptor interaction ,M10,1,0.39
0,1,0,-2.7,hsa04115,p53 signaling pathway ,M01,1,0.23
0,1,0,-2.3,R-HSA-9022692,Regulation of MECP2 expression and activity,M01,1,0.2
1,0,-3.1,0,R-HSA-212718,EGFR interacts with phospholipase C-gamma,M10,1,0.25
0,1,0,-5.5,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M01,1,0.35
0,1,0,-2.7,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M01,1,0.23
1,0,-2.8,0,R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",M10,1,0.24
1,0,-3,0,R-HSA-428359,Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,M10,1,0.25
0,1,0,-6.7,hsa04630,Jak-STAT signaling pathway ,M01,1,0.37
0,1,0,-3.6,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M01,1,0.28
1,0,-2.4,0,hsa04911,Insulin secretion,M10,1,0.21
1,0,-3.5,0,R-HSA-913709,O-linked glycosylation of mucins,M10,1,0.28
1,0,-8,0,ko04512,ECM-receptor interaction,M10,1,0.39
0,1,0,-6.1,R-HSA-1236975,Antigen processing-Cross presentation,M01,1,0.36
1,0,-2.7,0,ko04910,Insulin signaling pathway,M10,1,0.23
1,0,-2.2,0,hsa04917,Prolactin signaling pathway,M10,1,0.18
1,0,-2.6,0,R-HSA-3299685,Detoxification of Reactive Oxygen Species,M10,1,0.22
1,0,-6.2,0,R-HSA-1474228,Degradation of the extracellular matrix,M10,1,0.36
1,0,-15,0,R-HSA-6791226,Major pathway of rRNA processing in the nucleolus and cytosol,M10,1,0.44
1,0,-8.6,0,R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),M10,1,0.4
1,0,-2,0,ko00410,beta-Alanine metabolism,M10,1,0.17
1,0,-4.5,0,R-HSA-3772470,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,M10,1,0.32
0,1,0,-3.6,R-HSA-114604,GPVI-mediated activation cascade,M01,1,0.28
1,0,-2.4,0,M00130,"Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4",M10,1,0.2
1,0,-2.4,0,R-HSA-1250196,SHC1 events in ERBB2 signaling,M10,1,0.2
1,0,-4.8,0,ko05412,Arrhythmogenic right ventricular cardiomyopathy (ARVC),M10,1,0.33
0,1,0,-3.4,R-HSA-9005891,Loss of function of MECP2 in Rett syndrome,M01,1,0.27
0,1,0,-2.1,R-HSA-1247673,Erythrocytes take up oxygen and release carbon dioxide,M01,1,0.18
0,1,0,-3.9,R-HSA-5626467,RHO GTPases activate IQGAPs,M01,1,0.3
0,1,0,-5.6,R-HSA-111885,Opioid Signalling,M01,1,0.35
1,0,-2.2,0,R-HSA-8863795,Downregulation of ERBB2 signaling,M10,1,0.19
0,1,0,-2.4,R-HSA-72163,mRNA Splicing - Major Pathway,M01,1,0.2
1,0,-2.3,0,ko05215,Prostate cancer,M10,1,0.2
0,1,0,-5.7,R-HSA-5357801,Programmed Cell Death,M01,1,0.35
1,0,-4.8,0,hsa05412,Arrhythmogenic right ventricular cardiomyopathy (ARVC) ,M10,1,0.33
1,0,-2.1,0,R-HSA-9018678,Biosynthesis of specialized proresolving mediators (SPMs),M10,1,0.18
1,0,-2,0,R-HSA-199977,ER to Golgi Anterograde Transport,M10,1,0.17
1,0,-10,0,hsa05418,Fluid shear stress and atherosclerosis,M10,1,0.41
1,0,-3.4,0,R-HSA-3000157,Laminin interactions,M10,1,0.27
0,1,0,-3.5,R-HSA-8964616,G beta:gamma signalling through CDC42,M01,1,0.28
0,1,0,-2.4,R-HSA-397795,G-protein beta:gamma signalling,M01,1,0.2
0,1,0,-2.5,R-HSA-5674135,MAP2K and MAPK activation,M01,1,0.21
1,0,-3,0,R-HSA-373752,Netrin-1 signaling,M10,1,0.25
0,1,0,-4,R-HSA-9013404,RAC2 GTPase cycle,M01,1,0.3
0,1,0,-2.9,ko05211,Renal cell carcinoma,M01,1,0.24
1,0,-6.4,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M10,1,0.37
1,0,-2.1,0,R-HSA-5682910,LGI-ADAM interactions,M10,1,0.17
1,0,-2.8,0,R-HSA-428542,Regulation of commissural axon pathfinding by SLIT and ROBO,M10,1,0.24
1,0,-2.6,0,R-HSA-9032500,Activated NTRK2 signals through FYN,M10,1,0.22
1,0,-2.7,0,hsa00592,alpha-Linolenic acid metabolism ,M10,1,0.23
0,1,0,-3.1,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M01,1,0.26
1,0,-2.7,0,ko04540,Gap junction,M10,1,0.23
1,0,-2.3,0,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M10,1,0.2
1,0,-13,0,ko03010,Ribosome,M10,1,0.43
0,1,0,-8.8,ko05321,Inflammatory bowel disease (IBD),M01,1,0.4
0,1,0,-2.6,hsa04921,Oxytocin signaling pathway,M01,1,0.22
0,1,0,-3.4,R-HSA-166166,MyD88-independent TLR4 cascade ,M01,1,0.27
1,0,-5.5,0,R-HSA-3781865,Diseases of glycosylation,M10,1,0.35
0,1,0,-3.5,R-HSA-5620971,Pyroptosis,M01,1,0.28
1,0,-2.3,0,hsa04930,Type II diabetes mellitus ,M10,1,0.2
0,1,0,-11,R-HSA-372790,Signaling by GPCR,M01,1,0.42
1,0,-2.7,0,R-HSA-8848021,Signaling by PTK6,M10,1,0.23
1,0,-2.4,0,R-HSA-418990,Adherens junctions interactions,M10,1,0.21
1,0,-3.8,0,hsa04211,Longevity regulating pathway,M10,1,0.29
1,0,-2.6,0,hsa_M00047,Creatine pathway,M10,1,0.22
1,0,-3.8,0,R-HSA-5621480,Dectin-2 family,M10,1,0.29
1,0,-2.6,0,hsa05218,Melanoma ,M10,1,0.22
0,1,0,-2.5,R-HSA-389513,CTLA4 inhibitory signaling,M01,1,0.22
0,1,0,-28,R-HSA-1280215,Cytokine Signaling in Immune system,M01,1,0.47
1,0,-3.4,0,ko04974,Protein digestion and absorption,M10,1,0.27
0,1,0,-4.7,ko05203,Viral carcinogenesis,M01,1,0.32
1,0,-4.1,0,ko04550,Signaling pathways regulating pluripotency of stem cells,M10,1,0.3
0,1,0,-4,R-HSA-3858494,Beta-catenin independent WNT signaling,M01,1,0.3
1,0,-11,0,hsa00982,Drug metabolism - cytochrome P450 ,M10,1,0.42
0,1,0,-4.1,hsa04611,Platelet activation,M01,1,0.3
1,0,-14,0,R-HSA-8868773,rRNA processing in the nucleus and cytosol,M10,1,0.43
1,0,-2.4,0,ko05230,Central carbon metabolism in cancer,M10,1,0.21
0,1,0,-8.8,R-HSA-451927,Interleukin-2 family signaling,M01,1,0.4
0,1,0,-2.4,hsa04971,Gastric acid secretion,M01,1,0.2
1,0,-4.7,0,R-HSA-216083,Integrin cell surface interactions,M10,1,0.32
1,0,-25,0,R-HSA-72706,GTP hydrolysis and joining of the 60S ribosomal subunit,M10,1,0.46
1,0,-2.7,0,hsa04540,Gap junction ,M10,1,0.23
1,0,-2.7,0,R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,M10,1,0.23
1,0,-10,0,R-HSA-8953897,Cellular responses to external stimuli,M10,1,0.41
0,1,0,-6.9,R-HSA-380108,Chemokine receptors bind chemokines,M01,1,0.37
1,0,-2.2,0,ko04020,Calcium signaling pathway,M10,1,0.18
1,0,-2.9,0,ko04915,Estrogen signaling pathway,M10,1,0.24
1,0,-2.2,0,R-HSA-210500,Glutamate Neurotransmitter Release Cycle,M10,1,0.18
1,0,-5.9,0,ko05414,Dilated cardiomyopathy,M10,1,0.35
1,0,-2.2,0,R-HSA-193368,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,M10,1,0.18
1,0,-2,0,ko04657,IL-17 signaling pathway,M10,1,0.17
1,0,-4.3,0,R-HSA-3560801,Defective B3GAT3 causes JDSSDHD,M10,1,0.31
1,0,-3.2,0,hsa01521,EGFR tyrosine kinase inhibitor resistance,M10,1,0.26
1,0,-7,0,R-HSA-421270,Cell-cell junction organization,M10,1,0.38
1,0,-4.3,0,R-HSA-8978868,Fatty acid metabolism,M10,1,0.31
0,1,0,-3.3,hsa04210,Apoptosis ,M01,1,0.27
1,0,-4.2,0,R-HSA-983712,Ion channel transport,M10,1,0.31
1,0,-2.3,0,hsa04925,aldosterone synthesis and secretion,M10,1,0.2
1,0,-3,0,R-HSA-5083632,Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),M10,1,0.25
0,1,0,-12,hsa04612,Antigen processing and presentation ,M01,1,0.42
1,0,-3.1,0,R-HSA-5083636,Defective GALNT12 causes colorectal cancer 1 (CRCS1),M10,1,0.26
0,1,0,-3.3,ko04210,Apoptosis,M01,1,0.27
1,0,-2.4,0,R-HSA-9026527,Activated NTRK2 signals through PLCG1,M10,1,0.21
1,0,-5.1,0,R-HSA-71387,Metabolism of carbohydrates,M10,1,0.34
0,1,0,-4.4,R-HSA-5675221,Negative regulation of MAPK pathway,M01,1,0.32
0,1,0,-9.4,R-HSA-9020591,Interleukin-12 signaling,M01,1,0.4
1,0,-2.3,0,R-HSA-1482788,Acyl chain remodelling of PC,M10,1,0.2
1,0,-12,0,R-HSA-72662,"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",M10,1,0.42
0,1,0,-8.7,R-HSA-2172127,DAP12 interactions,M01,1,0.4
0,1,0,-12,ko04658,Th1 and Th2 cell differentiation,M01,1,0.42
0,1,0,-2.8,R-HSA-9020702,Interleukin-1 signaling,M01,1,0.23
1,0,-2.9,0,R-HSA-193775,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,M10,1,0.24
1,0,-3.3,0,M00004,Pentose phosphate pathway (Pentose phosphate cycle),M10,1,0.27
0,1,0,-3.2,R-HSA-8875360,InlB-mediated entry of Listeria monocytogenes into host cell,M01,1,0.26
0,1,0,-2.5,R-HSA-3928663,EPHA-mediated growth cone collapse,M01,1,0.22
0,1,0,-2.1,R-HSA-9013694,Signaling by NOTCH4,M01,1,0.18
1,0,-24,0,R-HSA-72613,Eukaryotic Translation Initiation,M10,1,0.46
0,1,0,-2.4,R-HSA-445717,Aquaporin-mediated transport,M01,1,0.21
1,0,-3.2,0,R-HSA-1971475,A tetrasaccharide linker sequence is required for GAG synthesis,M10,1,0.26
1,0,-12,0,hsa00980,Metabolism of xenobiotics by cytochrome P450 ,M10,1,0.42
1,0,-8.9,0,hsanan01,drug metabolism,M10,1,0.4
1,0,-13,0,R-HSA-72312,rRNA processing,M10,1,0.43
1,0,-8,0,R-HSA-156590,Glutathione conjugation,M10,1,0.39
1,0,-2.1,0,hsa00030,Pentose phosphate pathway ,M10,1,0.18
1,0,-2.2,0,hsa04213,Longevity regulating pathway - multiple species,M10,1,0.18
1,0,-5.9,0,R-HSA-373760,L1CAM interactions,M10,1,0.36
0,1,0,-9.2,R-HSA-983170,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",M01,1,0.4
1,0,-4.8,0,R-HSA-5668914,Diseases of metabolism,M10,1,0.33
1,0,-3.7,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M10,1,0.29
1,0,-25,0,R-HSA-9633012,Response of EIF2AK4 (GCN2) to amino acid deficiency,M10,1,0.46
1,0,-2.1,0,ko04912,GnRH signaling pathway,M10,1,0.17
1,0,-2,0,R-HSA-9664565,Signaling by ERBB2 KD Mutants,M10,1,0.17
0,1,0,-2,R-HSA-8939902,Regulation of RUNX2 expression and activity,M01,1,0.17
0,1,0,-2.1,R-HSA-195253,Degradation of beta-catenin by the destruction complex,M01,1,0.18
0,1,0,-7.7,R-HSA-5673001,RAF/MAP kinase cascade,M01,1,0.39
1,0,-6.7,0,R-HSA-2129379,Molecules associated with elastic fibres,M10,1,0.37
1,0,-2.2,0,ko00591,Linoleic acid metabolism,M10,1,0.19
1,0,-2.2,0,ko04970,Salivary secretion,M10,1,0.18
1,0,-2.3,0,R-HSA-5576892,Phase 0 - rapid depolarisation,M10,1,0.2
0,1,0,-4.7,hsa04064,NF-kappa B signaling pathway,M01,1,0.32
1,0,-3.9,0,hsa05224,Breast cancer,M10,1,0.3
1,0,-4.7,0,ko04610,Complement and coagulation cascades,M10,1,0.32
0,1,0,-17,ko04650,Natural killer cell mediated cytotoxicity,M01,1,0.44
0,1,0,-2.5,R-HSA-879415,Advanced glycosylation endproduct receptor signaling,M01,1,0.22
0,1,0,-2,hsa04924,Renin secretion,M01,1,0.17
1,0,-2.1,0,R-HSA-1306955,GRB7 events in ERBB2 signaling,M10,1,0.18
0,1,0,-5.9,R-HSA-202424,Downstream TCR signaling,M01,1,0.35
1,0,-2.8,0,ko00350,Tyrosine metabolism,M10,1,0.24
1,0,-2.6,0,hsa01522,Endocrine resistance,M10,1,0.22
0,1,0,-2.9,hsa05211,Renal cell carcinoma ,M01,1,0.24
0,1,0,-2.5,R-HSA-162906,HIV Infection,M01,1,0.22
1,0,-4.7,0,hsa04610,Complement and coagulation cascades ,M10,1,0.32
1,0,-2.4,0,R-HSA-83936,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,M10,1,0.2
1,0,-5.3,0,ko00590,Arachidonic acid metabolism,M10,1,0.34
0,1,0,-2.5,R-HSA-114452,Activation of BH3-only proteins,M01,1,0.22
0,1,0,-3.5,R-HSA-500792,GPCR ligand binding,M01,1,0.28
0,1,0,-5.6,R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),M01,1,0.35
0,1,0,-2,R-HSA-6806003,Regulation of TP53 Expression and Degradation,M01,1,0.17
1,0,-2.3,0,hsa05210,Colorectal cancer ,M10,1,0.2
1,0,-5,0,R-HSA-420029,Tight junction interactions,M10,1,0.33
1,0,-2.8,0,hsa04392,Hippo signaling pathway -multiple species,M10,1,0.24
0,1,0,-3.6,R-HSA-162909,Host Interactions of HIV factors,M01,1,0.28
1,0,-6.7,0,ko04933,AGE-RAGE signaling pathway in diabetic complications,M10,1,0.37
1,0,-4.8,0,ko00565,Ether lipid metabolism,M10,1,0.33
1,0,-2.8,0,R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",M10,1,0.24
1,0,-5.6,0,R-HSA-975634,Retinoid metabolism and transport,M10,1,0.35
1,0,-5.1,0,R-HSA-6806667,Metabolism of fat-soluble vitamins,M10,1,0.34
1,0,-2.9,0,R-HSA-5336415,Uptake and function of diphtheria toxin,M10,1,0.24
1,0,-27,0,R-HSA-72689,Formation of a pool of free 40S subunits,M10,1,0.46
0,1,0,-3,R-HSA-428930,Thromboxane signalling through TP receptor,M01,1,0.25
0,1,0,-3,hsa00232,Caffeine metabolism,M01,1,0.25
1,0,-2.5,0,ko05212,Pancreatic cancer,M10,1,0.21
1,0,-2.9,0,R-HSA-166663,Initial triggering of complement,M10,1,0.25
1,0,-2.8,0,ko04392,Hippo signaling pathway -multiple species,M10,1,0.24
1,0,-20,0,R-HSA-1799339,SRP-dependent cotranslational protein targeting to membrane,M10,1,0.45
0,1,0,-3.3,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M01,1,0.27
0,1,0,-3.8,R-HSA-3700989,Transcriptional Regulation by TP53,M01,1,0.29
1,0,-8.6,0,hsa00480,Glutathione metabolism ,M10,1,0.4
0,1,0,-3.4,R-HSA-8878171,Transcriptional regulation by RUNX1,M01,1,0.28
1,0,-5.3,0,hsa00590,Arachidonic acid metabolism ,M10,1,0.34
1,0,-2.1,0,hsa05034,Alcoholism,M10,1,0.17
1,0,-4.8,0,R-HSA-2672351,Stimuli-sensing channels,M10,1,0.33
1,0,-2.4,0,R-HSA-196757,Metabolism of folate and pterines,M10,1,0.2
1,0,-2.5,0,hsa00330,Arginine and proline metabolism ,M10,1,0.22
0,1,0,-3.2,R-HSA-373076,Class A/1 (Rhodopsin-like receptors),M01,1,0.26
0,1,0,-3.9,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M01,1,0.3
1,0,-2.5,0,hsa05212,Pancreatic cancer ,M10,1,0.21
0,1,0,-2.5,R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,M01,1,0.22
1,0,-26,0,R-HSA-156827,L13a-mediated translational silencing of Ceruloplasmin expression,M10,1,0.46
0,1,0,-4.4,ko04621,NOD-like receptor signaling pathway,M01,1,0.32
1,0,-23,0,R-HSA-72764,Eukaryotic Translation Termination,M10,1,0.46
0,1,0,-3.3,R-HSA-5357956,TNFR1-induced NFkappaB signaling pathway,M01,1,0.27
1,0,-4.2,0,ko00010,Glycolysis / Gluconeogenesis,M10,1,0.31
0,1,0,-13,hsa04658,Th1 and Th2 cell differentiation,M01,1,0.43
1,0,-2.4,0,R-HSA-166658,Complement cascade,M10,1,0.21
1,0,-2.6,0,M00047,Creatine pathway,M10,1,0.22
0,1,0,-3.1,hsa05164,Influenza A,M01,1,0.26
1,0,-3.6,0,hsa04261,Adrenergic signaling in cardiomyocytes,M10,1,0.28
0,1,0,-4.8,ko04064,NF-kappa B signaling pathway,M01,1,0.33
1,0,-4.5,0,R-HSA-1442490,Collagen degradation,M10,1,0.32
0,1,0,-2,R-HSA-2514859,"Inactivation, recovery and regulation of the phototransduction cascade",M01,1,0.17
0,1,0,-8,R-HSA-5684996,MAPK1/MAPK3 signaling,M01,1,0.39
0,1,0,-3.3,R-HSA-195721,Signaling by WNT,M01,1,0.26
0,1,0,-3.2,ko04728,Dopaminergic synapse,M01,1,0.26
0,1,0,-2.4,R-HSA-975110,TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling,M01,1,0.21
0,1,0,-2.9,R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,M01,1,0.24
0,1,0,-8.9,R-HSA-447115,Interleukin-12 family signaling,M01,1,0.4
1,0,-2.8,0,ko00830,Retinol metabolism,M10,1,0.24
0,1,0,-8,ko05162,Measles,M01,1,0.39
1,0,-2.8,0,hsa00340,Histidine metabolism ,M10,1,0.24
1,0,-3.3,0,hsa_M00004,Pentose phosphate pathway (Pentose phosphate cycle),M10,1,0.27
0,1,0,-3.1,R-HSA-392517,Rap1 signalling,M01,1,0.26
1,0,-2.2,0,hsa04330,Notch signaling pathway ,M10,1,0.19
1,0,-2.2,0,R-HSA-977225,Amyloid fiber formation,M10,1,0.19
1,0,-2.5,0,ko00330,Arginine and proline metabolism,M10,1,0.22
1,0,-4.3,0,R-HSA-3560783,"Defective B4GALT7 causes EDS, progeroid type",M10,1,0.31
0,1,0,-2.9,R-HSA-75893,TNF signaling,M01,1,0.24
0,1,0,-3.6,hsa04623,Cytosolic DNA-sensing pathway ,M01,1,0.28
1,0,-3.4,0,R-HSA-2142850,Hyaluronan biosynthesis and export,M10,1,0.27
1,0,-2.3,0,ko05210,Colorectal cancer,M10,1,0.2
1,0,-2.2,0,hsa00760,Nicotinate and nicotinamide metabolism ,M10,1,0.19
1,0,-4.3,0,R-HSA-71384,Ethanol oxidation,M10,1,0.31
0,1,0,-2.8,R-HSA-6806834,Signaling by MET,M01,1,0.23
1,0,-4.9,0,hsa04931,insulin resistance,M10,1,0.33
0,1,0,-4,R-HSA-422356,Regulation of insulin secretion,M01,1,0.3
1,0,-21,0,R-HSA-975957,Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),M10,1,0.45
1,0,-5.2,0,hsa05150,Staphylococcus aureus infection,M10,1,0.34
0,1,0,-10,hsa04940,Type I diabetes mellitus ,M01,1,0.41
0,1,0,-2.4,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M01,1,0.2
0,1,0,-2.4,R-HSA-156581,Methylation,M01,1,0.21
0,1,0,-10,ko04940,Type I diabetes mellitus,M01,1,0.41
1,0,-2.3,0,R-HSA-1614635,Sulfur amino acid metabolism,M10,1,0.2
1,0,-2.6,0,R-HSA-194068,Bile acid and bile salt metabolism,M10,1,0.22
1,0,-2.6,0,R-HSA-157858,Gap junction trafficking and regulation,M10,1,0.22
0,1,0,-2.4,hsa04071,Sphingolipid signaling pathway,M01,1,0.2
1,0,-2.5,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M10,1,0.22
1,0,-2.6,0,ko01522,Endocrine resistance,M10,1,0.22
1,0,-3.5,0,R-HSA-9006931,Signaling by Nuclear Receptors,M10,1,0.28
1,0,-2.2,0,ko04925,Aldosterone synthesis and secretion,M10,1,0.19
0,1,0,-17,ko04660,T cell receptor signaling pathway,M01,1,0.44
0,1,0,-5.4,R-HSA-936440,Negative regulators of DDX58/IFIH1 signaling,M01,1,0.34
0,1,0,-3.4,R-HSA-6807004,Negative regulation of MET activity,M01,1,0.27
0,1,0,-2.8,hsa04720,Long-term potentiation ,M01,1,0.24
1,0,-2.9,0,ko00260,"Glycine, serine and threonine metabolism",M10,1,0.24
1,0,-3.2,0,R-HSA-445095,Interaction between L1 and Ankyrins,M10,1,0.26
0,1,0,-10,ko04062,Chemokine signaling pathway,M01,1,0.41
1,0,-14,0,R-HSA-397014,Muscle contraction,M10,1,0.43
0,1,0,-2.5,R-HSA-140342,Apoptosis induced DNA fragmentation,M01,1,0.22
1,0,-21,0,R-HSA-927802,Nonsense-Mediated Decay (NMD),M10,1,0.45
0,1,0,-3.7,R-HSA-4086398,Ca2+ pathway,M01,1,0.29
0,1,0,-2.4,ko05145,Toxoplasmosis,M01,1,0.21
0,1,0,-2.1,R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,M01,1,0.18
1,0,-2.4,0,R-HSA-1483206,Glycerophospholipid biosynthesis,M10,1,0.21
1,0,-2.7,0,R-HSA-193807,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,M10,1,0.23
1,0,-2.9,0,hsa00260,"Glycine, serine and threonine metabolism ",M10,1,0.24
0,1,0,-2.2,R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,M01,1,0.19
0,1,0,-4.4,R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,M01,1,0.31
0,1,0,-3,R-HSA-9656223,Signaling by RAF1 mutants,M01,1,0.25
0,1,0,-2.9,R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,M01,1,0.24
1,0,-9.8,0,R-HSA-156580,Phase II - Conjugation of compounds,M10,1,0.41
1,0,-7.9,0,R-HSA-556833,Metabolism of lipids,M10,1,0.39
1,0,-10,0,hsa05204,Chemical carcinogenesis,M10,1,0.41
1,0,-6.2,0,R-HSA-1566948,Elastic fibre formation,M10,1,0.36
0,1,0,-4.9,R-HSA-5627123,RHO GTPases activate PAKs,M01,1,0.33
0,1,0,-2.3,R-HSA-9604323,Negative regulation of NOTCH4 signaling,M01,1,0.2
0,1,0,-5.7,R-HSA-6783783,Interleukin-10 signaling,M01,1,0.35
0,1,0,-3.4,R-HSA-9697154,Disorders of Nervous System Development,M01,1,0.27
1,0,-2.1,0,R-HSA-1482925,Acyl chain remodelling of PG,M10,1,0.18
0,1,0,-3.6,ko04623,Cytosolic DNA-sensing pathway,M01,1,0.28
1,0,-2.8,0,R-HSA-193648,NRAGE signals death through JNK,M10,1,0.24
1,0,-5.9,0,hsa05414,Dilated cardiomyopathy ,M10,1,0.35
0,1,0,-4.1,R-HSA-112409,RAF-independent MAPK1/3 activation,M01,1,0.3
0,1,0,-6.2,R-HSA-199991,Membrane Trafficking,M01,1,0.36
1,0,-2.5,0,R-HSA-1963642,PI3K events in ERBB2 signaling,M10,1,0.21
0,1,0,-17,ko04060,Cytokine-cytokine receptor interaction,M01,1,0.44
1,0,-2.7,0,R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,M10,1,0.23
1,0,-2.8,0,ko00561,Glycerolipid metabolism,M10,1,0.24
1,0,-3.8,0,R-HSA-2142712,Synthesis of 12-eicosatetraenoic acid derivatives,M10,1,0.29
1,0,-14,0,R-HSA-9010553,Regulation of expression of SLITs and ROBOs,M10,1,0.43
1,0,-5.1,0,R-HSA-186797,Signaling by PDGF,M10,1,0.34
1,0,-3.9,0,R-HSA-419037,NCAM1 interactions,M10,1,0.29
0,1,0,-12,R-HSA-388396,GPCR downstream signalling,M01,1,0.42
1,0,-2.2,0,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,M10,1,0.18
1,0,-2.8,0,hsa00830,Retinol metabolism ,M10,1,0.24
0,1,0,-3.9,hsa04114,Oocyte meiosis ,M01,1,0.3
1,0,-2.4,0,M00006,"Pentose phosphate pathway, oxidative phase, glucose 6P => ribulose 5P",M10,1,0.21
0,1,0,-3.4,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M01,1,0.27
0,1,0,-2.1,R-HSA-9664424,Cell recruitment (pro-inflammatory response),M01,1,0.18
0,1,0,-2.7,R-HSA-9022535,Loss of phosphorylation of MECP2 at T308,M01,1,0.23
1,0,-6,0,hsa03320,PPAR signaling pathway ,M10,1,0.36
1,0,-2.3,0,ko04930,Type II diabetes mellitus,M10,1,0.2
0,1,0,-2.2,R-HSA-429947,Deadenylation of mRNA,M01,1,0.19
1,0,-3.4,0,ko04261,Adrenergic signaling in cardiomyocytes,M10,1,0.27
1,0,-6,0,ko04310,Wnt signaling pathway,M10,1,0.36
1,0,-2.2,0,ko05217,Basal cell carcinoma,M10,1,0.18
1,0,-4.8,0,hsa00565,Ether lipid metabolism ,M10,1,0.33
1,0,-3.3,0,R-HSA-9664420,Killing mechanisms,M10,1,0.27
0,1,0,-3,hsa05100,Bacterial invasion of epithelial cells,M01,1,0.25
1,0,-5.1,0,R-HSA-5576891,Cardiac conduction,M10,1,0.34
0,1,0,-2.7,R-HSA-6803207,TP53 Regulates Transcription of Caspase Activators and Caspases,M01,1,0.23
1,0,-3.1,0,R-HSA-5083625,Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),M10,1,0.26
0,1,0,-2.3,R-HSA-2214320,Anchoring fibril formation,M01,1,0.2
1,0,-2.7,0,hsa04919,thyroid hormone signaling pathway,M10,1,0.23
1,0,-2,0,hsa01523,Antifolate resistance,M10,1,0.17
0,1,0,-3.2,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M01,1,0.26
1,0,-2.4,0,hsa_M00130,"Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4",M10,1,0.2
1,0,-2.2,0,ko05120,Epithelial cell signaling in Helicobacter pylori infection,M10,1,0.19
1,0,-2.7,0,hsa04910,Insulin signaling pathway ,M10,1,0.23
0,1,0,-2.2,R-HSA-391160,Signal regulatory protein family interactions,M01,1,0.18
1,0,-2.6,0,ko00564,Glycerophospholipid metabolism,M10,1,0.23
0,1,0,-12,R-HSA-202403,TCR signaling,M01,1,0.42
0,1,0,-7.8,R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,M01,1,0.39
1,0,-2,0,R-HSA-2029485,Role of phospholipids in phagocytosis,M10,1,0.17
0,1,0,-2.4,R-HSA-442720,CREB1 phosphorylation through the activation of Adenylate Cyclase,M01,1,0.21
1,0,-2.3,0,R-HSA-3595174,"Defective CHST14 causes EDS, musculocontractural type",M10,1,0.2
1,0,-2.1,0,R-HSA-948021,Transport to the Golgi and subsequent modification,M10,1,0.17
0,1,0,-6.1,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M01,1,0.36
1,0,-2.9,0,R-HSA-3656253,"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",M10,1,0.24
1,0,-3,0,R-HSA-1227986,Signaling by ERBB2,M10,1,0.25
